KRAS Proto-oncogene GTPase (Mutant Forms Including G12D) (KRAS)

KRAS is a small GTPase protein that acts as a molecular switch, cycling between active (GTP-bound) and inactive (GDP-bound) states. Mutations, particularly G12D, lock KRAS in the active form, driving uncontrolled cell growth and oncogenesis, especially in pancreatic, colorectal, and lung cancers. The G12D mutation involves a substitution of glycine with aspartic acid at codon 12. It is associated with poorer prognosis and increased immunosuppression. While historically "undruggable," recent efforts have led to the development of inhibitors like MRTX1133 targeting mutant KRAS-G12D. Detection is typically achieved through NGS or PCR-based assays.

Other names

Kirsten rat sarcoma viral oncogene homologKRAS-G12Dv-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog

Direct KRAS-G12D inhibition